Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to shrink hard-to-treat tumors

NCT ID NCT05176483

Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth. About 1,300 participants with various cancers, including kidney, prostate, and lung cancer, will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 1,394 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic. * Dose-Escalation Cohorts: Participants with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. * Expansion Cohort 1 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component who have not received prior systemic therapy. * Note: Prior non-vascular endothelial growth factor (VEGF) targeted adjuvant or neoadjuvant is allowed if disease recurrence occurred 6 months after the last dose. * Expansion Cohort 2 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component. * Must have radiographically progressed after a combination therapy consisting of a Programmed Cell Death Protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) targeting monoclonal antibody (mAb) with a Vascular endothelial growth factor (receptor) tyrosine kinase inhibitor (VEGFR-TKI) or a PD-1 targeting mAb with a CTLA-4 mAb as the preceding line of therapy. * Must have received no more than one prior systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma. * Expansion Cohort 3 (mCRPC): Men with metastatic adenocarcinoma of the prostate. * Must have progressed during or after one novel hormone therapy (NHT) given for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer (CSPC), M0 CRPC, or mCRPC. * Expansion Cohort 4 (UC, ICI-naive): Participants with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra). * Must have progressed during or after prior first-line platinum-based combination therapy, including participants who received prior neoadjuvant or adjuvant platinum-containing therapy with disease recurrence \< 12 months from the end of last therapy. * Must have received no more than 1 prior line of systemic anticancer therapy for unresectable, locally advanced or metastatic disease. * Expansion Cohort 5 (post enfortumab vedotin \[EV\] and ICI): Participants with histologically confirmed unresectable, locally advanced or metastatic predominant urothelial carcinoma. * Progressive disease following prior EV or ineligible for EV, and progression following prior PD-1/PD-L1 inhibitor or ineligible for PD-1/PD-L1 inhibitor. * Prior receipt of platinum-based therapy allowed but not required. * Prior therapy with other agents allowed but not required. * Expansion Cohort 6 (nccRCC): Participants with unresectable advanced or metastatic nccRCC of the following subtypes: Papillary, unclassified RCC, and translocation-associated, Fumarate Hydratase (FH) deficient and Succinate Dehydrogenase (SDH) deficient. Among the eligible histologic subtypes, sarcomatoid features are allowed. * No prior systemic anticancer therapy is allowed except adjuvant or neoadjuvant therapy if disease recurrence occurred at least 6 months after the last dose. * Expansion Cohort 7 (HCC): Participants with locally advanced, or metastatic and/or unresectable HCC that is not amenable to curative treatment or locoregional therapy. * Expansion Cohort 8 (NSCLC): Participants with Stage IV non-squamous NSCLC with positive PD-L1 expression (tumor proportion score \[TPS\] 1-49%) and without prior systemic anticancer therapy for metastatic disease. * Expansion Cohort 9 (NSCLC): Participants with Stage IV non-squamous NSCLC who have radiologically progressed following treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) for metastatic disease. * Expansion Cohort 10 (CRC): Participants with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum. * Expansion Cohort 11 (HNSCC): Participant with inoperable, refractory, recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. PD-L1 combined positive score (CPS) ≥1. * Expansion Cohort 12 (ccRCC): Participants with unresectable advance or metastatic RCC with a clear cell component, including participants who also have a sacromatoid feature. * Must have received no more than two prior lines of systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma * Expansion Cohort 13 and Cohort 14 (ccRCC 1L): Participants with unresectable advanced or metastatic RCC with a clear component, including participants who also have a sacromatoid feature. * Cohort 15 (mCRPC, post-ARPI, visceral metastases): Men with metastatic adenocarcinoma of the prostate. * Cohort 16 (Drug-drug interaction \[DDI\]): * Participants with a solid tumor that is unresectable or metastatic and for which life prolonging therapies do not exist or available therapies are intolerable or no longer effective. * Able to swallow capsules or tablets. * For all Expansion Cohorts except Cohort 3: Measurable disease per RECIST 1.1 as determined by the Investigator. * For Expansion Cohorts 1 - 11 Only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained. * Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy. * Karnofsky Performance Status (KPS) ≥ 70%. * Adequate organ and marrow function. * Sexually active fertile participants and their partners must agree to use highly effective methods of contraception. * Females of childbearing potential must not be pregnant at screening. Key Exclusion Criteria: * For all Dose-Escalation cohorts: Prior treatment with zanzalintinib. For all Expansion Cohorts: Prior treatment with zanzalintinib, nivolumab, ipilimumab or relatlimab with the following exceptions: Prior PD-1/PD-L1, Lymphocyte-activation gene 3 (LAG-3) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) targeting therapy for locally advanced or metastatic disease is allowed for Cohort 2 (ccRCC), Cohort 5 (UC), Cohort 9 (NSCLC), and Cohort 12 (ccRCC), and prior treatment in the neoadjuvant or adjuvant setting is allowed for Cohort 13 and Cohort 14 (ccRCC 1L). * For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC), Cohort 10 (CRC), and Cohort 12: Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment. * For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment. * For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC) and Cohort 10 (CRC), and Cohort 12: Receipt of any type of anticancer antibody or systemic chemotherapy within 4 weeks before first dose of study treatment. * Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment. * Prior external radiation therapy for bone metastasis within 2 weeks, for other tumor sites within 4 weeks, and prior radium-223 therapy within 6 weeks before first dose of study treatment, unless otherwise specified. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. * Concomitant anticoagulation with oral anticoagulants, except for specified direct factor Xa inhibitors. * Administration of a live, attenuated vaccine within 30 days prior to first dose. * Uncontrolled, significant intercurrent or recent illness. * Corrected QT interval calculated by the Fridericia formula (QTcF) \> 460 ms for females and \> 450 ms for males per electrocardiogram (ECG) within 14 days before first dose of study treatment. * Participants with inadequately treated adrenal insufficiency. * Pregnant or lactating females. * Any other active malignancy within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6. * For Cohort 2 (ccRCC, 2L): Receipt of a prior triplet therapy including a VEGFR-TKI, a PD1 targeting mAb, and a CTLA-4 mAb. * For Cohort 3 (mCRPC): Receipt of a taxane-based chemotherapy for mCRPC. * For Cohort 4 (UC, ICI-naïve): Participants who have had recurrence within the 6 months of completing adjuvant anti-PD-(L)1 treatment. * For Cohort 6 (nccRCC, 1L): Participants with chromophobe, renal medullary carcinoma, or pure collecting duct nccRCC. * For Cohort 7 (HCC): * Documented hepatic encephalopathy (HE) within 6 months before the first dose. * Clinically meaningful ascites (ie, ascites requiring paracentesis or escalation in diuretics) within 6 months before randomization. * Participants who have received any local anticancer therapy including surgery, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation (MWA), transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose. * Participants with known fibrolamellar carcinoma, sarcomatoid HCC, or mixed hepatocellular cholangiocarcinoma * For Cohort 10 (CRC, 2L+): Receipt of prior therapy with regorafenib and/or trifluridine + tipiracil (TAS-102). * For Cohort 11 (HNSCC): Primary tumor site of the nasopharyngeal area. * For Cohorts 1 (ccRCC, 1L), 2 (ccRCC, 2L), 4, 5 (UC), 7 (HCC), 8 (NSCLC 1L PD-L1 low), 9 (NSCLC, 2L+), 10 (CRC, microsatellite stable \[MSS\], 2L+), and 11 (HNSCC): * Troponin T (TnT) or I (TnI) \> 2 × institutional upper limit of normal (ULN). * For Cohort 16 (DDI): * Known hypersensitivity to midazolam, warfarin, omeprazole, or caffeine. * History of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within 3 months prior to first dose of study treatment on Day 1. * Primary liver tumor. * Unable to refrain from or anticipates the use of the following: * Any drugs known to be inducers or inhibitors of CYP3A4, CYP2C9, CYP2C19, and/or CYP1A2 within 14 days before the first dose of study treatment on Day 1 through the DDI assessments on Day 20. * Drugs that are contraindicated with midazolam, warfarin, omeprazole, and/or caffeine during the DDI assessment part. * Caffeine-containing beverages, products, and foods at least 3 days prior to and 3 days after probe substrate cocktail administration on Day 1 and Day 16. * Poor peripheral venous access. Note: Additional Inclusion and Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clear cell renal cell carcinoma (CCRCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma colorectal cancer colorectal neoplasm head and neck squamous cell carcinoma hepatocellular carcinoma metastatic prostate carcinoma neoplasm non-small cell lung carcinoma nonpapillary renal cell carcinoma renal cell carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clear cell renal cell carcinoma (CCRCC) Colorectal cancer (CRC) Drug drug interaction (DDI) Head and neck squamous cell carcinoma HNSCC Hepatocellular carcinoma (HCC) Metastatic castration-resistant prostate cancer (MCRPC) Non-clear cell renal cell carcinoma (NCCRCC) Non-small cell lung cancer (NSCLC) Renal cell carcinoma (RCC) Solid tumor Urothelial carcinoma (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    114 sites in 13 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Exelixis Clinical Site #1

    RECRUITING

    Tucson, Arizona, 85711, United States

  • Exelixis Clinical Site #10

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Exelixis Clinical Site #100

    RECRUITING

    Madrid, 28046, Spain

  • Exelixis Clinical Site #101

    RECRUITING

    Milan, 20132, Italy

  • Exelixis Clinical Site #102

    RECRUITING

    Nürtingen, 72622, Germany

  • Exelixis Clinical Site #103

    RECRUITING

    Essen, 45147, Germany

  • Exelixis Clinical Site #104

    RECRUITING

    Hershey, Pennsylvania, 17033, United States

  • Exelixis Clinical Site #105

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Exelixis Clinical Site #106

    RECRUITING

    Wein, 1090, Austria

  • Exelixis Clinical Site #107

    RECRUITING

    Trier, 54292, Germany

  • Exelixis Clinical Site #108

    RECRUITING

    Heidelberg, 69120, Germany

  • Exelixis Clinical Site #109

    WITHDRAWN

    Lyon, 69008, France

  • Exelixis Clinical Site #11

    RECRUITING

    Gainesville, Florida, 32610, United States

  • Exelixis Clinical Site #110

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Exelixis Clinical Site #111

    RECRUITING

    Dallas, Texas, 75246, United States

  • Exelixis Clinical Site #112

    COMPLETED

    München, 81737, Germany

  • Exelixis Clinical Site #113

    RECRUITING

    Hamburg, 22763, Germany

  • Exelixis Clinical Site #114

    RECRUITING

    Wroclaw, 53-413, Poland

  • Exelixis Clinical Site #115

    RECRUITING

    Villejuif, 94805, France

  • Exelixis Clinical Site #116

    RECRUITING

    Albury, 2640, Australia

  • Exelixis Clinical Site #117

    RECRUITING

    Bologna, 40138, Italy

  • Exelixis Clinical Site #118

    RECRUITING

    Clermont-Ferrand, 63011, France

  • Exelixis Clinical Site #119

    RECRUITING

    Santander, 39008, Spain

  • Exelixis Clinical Site #12

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Exelixis Clinical Site #120

    RECRUITING

    L'Hospitalet de Llobregat, 08908, Spain

  • Exelixis Clinical Site #121

    RECRUITING

    Ancona, 60020, Italy

  • Exelixis Clinical Site #122

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Exelixis Clinical Site #123

    RECRUITING

    Palo Alto, California, 94304, United States

  • Exelixis Clinical Site #13

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Exelixis Clinical Site #14

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Exelixis Clinical Site #15

    RECRUITING

    Barcelona, 08036, Spain

  • Exelixis Clinical Site #16

    RECRUITING

    Brisbane, 4102, Australia

  • Exelixis Clinical Site #18

    RECRUITING

    Pamplona, 31008, Spain

  • Exelixis Clinical Site #19

    RECRUITING

    Madrid, 28041, Spain

  • Exelixis Clinical Site #2

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Exelixis Clinical Site #20

    RECRUITING

    Bydgoszcz, 85-796, Poland

  • Exelixis Clinical Site #21

    COMPLETED

    Chur, 7000, Switzerland

  • Exelixis Clinical Site #22

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Exelixis Clinical Site #23

    RECRUITING

    Seville, 41013, Spain

  • Exelixis Clinical Site #24

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Exelixis Clinical Site #25

    RECRUITING

    Valencia, 46026, Spain

  • Exelixis Clinical Site #26

    RECRUITING

    Chicago, Illinois, 60612, United States

  • Exelixis Clinical Site #27

    RECRUITING

    Barcelona, 08041, Spain

  • Exelixis Clinical Site #28

    RECRUITING

    Gdansk, 80-219, Poland

  • Exelixis Clinical Site #29

    RECRUITING

    Vienna, 1020, Austria

  • Exelixis Clinical Site #3

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Exelixis Clinical Site #30

    RECRUITING

    Grafton, 1023, New Zealand

  • Exelixis Clinical Site #31

    COMPLETED

    Salzburg, 5020, Austria

  • Exelixis Clinical Site #32

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • Exelixis Clinical Site #33

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Exelixis Clinical Site #34

    RECRUITING

    Otwock, 05-400, Poland

  • Exelixis Clinical Site #35

    RECRUITING

    Birtinya, 4575, Australia

  • Exelixis Clinical Site #36

    RECRUITING

    Sydney, 2109, Australia

  • Exelixis Clinical Site #37

    RECRUITING

    Kortrijk, 8500, Belgium

  • Exelixis Clinical Site #38

    RECRUITING

    Ẕerifin, 7030000, Israel

  • Exelixis Clinical Site #39

    COMPLETED

    Anderlecht, 1070, Belgium

  • Exelixis Clinical Site #4

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Exelixis Clinical Site #40

    RECRUITING

    Naples, 80131, Italy

  • Exelixis Clinical Site #41

    RECRUITING

    Badajoz, 06080, Spain

  • Exelixis Clinical Site #42

    RECRUITING

    Saint Leonards, 2065, Australia

  • Exelixis Clinical Site #43

    RECRUITING

    Madrid, 28034, Spain

  • Exelixis Clinical Site #44

    RECRUITING

    Winterthur, 8401, Switzerland

  • Exelixis Clinical Site #45

    RECRUITING

    Hamilton, 3204, New Zealand

  • Exelixis Clinical Site #46

    RECRUITING

    Austin, Texas, 78705, United States

  • Exelixis Clinical Site #47

    RECRUITING

    Miami, Florida, 33136, United States

  • Exelixis Clinical Site #48

    RECRUITING

    Celebration, Florida, 34747, United States

  • Exelixis Clinical Site #49

    ACTIVE_NOT_RECRUITING

    Newark, Delaware, 19713, United States

  • Exelixis Clinical Site #5

    ACTIVE_NOT_RECRUITING

    Omaha, Nebraska, 68130, United States

  • Exelixis Clinical Site #50

    RECRUITING

    Plano, Texas, 75075, United States

  • Exelixis Clinical Site #51

    RECRUITING

    Portland, Oregon, 97239, United States

  • Exelixis Clinical Site #52

    RECRUITING

    Jerusalem, 9112001, Israel

  • Exelixis Clinical Site #53

    RECRUITING

    Barcelona, 08035, Spain

  • Exelixis Clinical Site #54

    RECRUITING

    Poznan, 60-569, Poland

  • Exelixis Clinical Site #55

    RECRUITING

    Las Vegas, Nevada, 89052, United States

  • Exelixis Clinical Site #56

    RECRUITING

    Valencia, 46010, Spain

  • Exelixis Clinical Site #57

    RECRUITING

    Madrid, 28033, Spain

  • Exelixis Clinical Site #58

    RECRUITING

    Madrid, 28040, Spain

  • Exelixis Clinical Site #59

    RECRUITING

    Santa Barbara, California, 93463, United States

  • Exelixis Clinical Site #6

    RECRUITING

    New York, New York, 10065, United States

  • Exelixis Clinical Site #60

    RECRUITING

    New York, New York, 10032, United States

  • Exelixis Clinical Site #61

    RECRUITING

    Plantation, Florida, 33322, United States

  • Exelixis Clinical Site #62

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Exelixis Clinical Site #63

    RECRUITING

    Saint-Herblain, 44805, France

  • Exelixis Clinical Site #64

    RECRUITING

    Nice, 06189, France

  • Exelixis Clinical Site #65

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Exelixis Clinical Site #66

    RECRUITING

    Charlottesville, Virginia, 22903, United States

  • Exelixis Clinical Site #67

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Exelixis Clinical Site #68

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Exelixis Clinical Site #69

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Exelixis Clinical Site #7

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Exelixis Clinical Site #70

    RECRUITING

    Tyler, Texas, 75601, United States

  • Exelixis Clinical Site #71

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Exelixis Clinical Site #72

    RECRUITING

    Haifa, 3109601, Israel

  • Exelixis Clinical Site #73

    RECRUITING

    Irving, Texas, 75063, United States

  • Exelixis Clinical Site #74

    RECRUITING

    Ravenna, 48121, Italy

  • Exelixis Clinical Site #75

    RECRUITING

    Strasbourg, 67200, France

  • Exelixis Clinical Site #76

    RECRUITING

    Syracuse, New York, 13210, United States

  • Exelixis Clinical Site #77

    RECRUITING

    Madrid, 28040, Spain

  • Exelixis Clinical Site #78

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Exelixis Clinical Site #79

    RECRUITING

    Caen, 14076, France

  • Exelixis Clinical Site #8

    RECRUITING

    Tampa, Florida, 33612, United States

  • Exelixis Clinical Site #80

    RECRUITING

    Rennes, 35042, France

  • Exelixis Clinical Site #81

    RECRUITING

    Milan, 20141, Italy

  • Exelixis Clinical Site #82

    RECRUITING

    Herne, 44625, Germany

  • Exelixis Clinical Site #83

    RECRUITING

    Paris, 75010, France

  • Exelixis Clinical Site #84

    RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

  • Exelixis Clinical Site #85

    RECRUITING

    Besançon, 25030, France

  • Exelixis Clinical Site #86

    RECRUITING

    Beersheba, 8410101, Israel

  • Exelixis Clinical Site #87

    RECRUITING

    Littleton, Colorado, 80124, United States

  • Exelixis Clinical Site #88

    RECRUITING

    East Brunswick, New Jersey, 08816, United States

  • Exelixis Clinical Site #89

    RECRUITING

    Dallas, Texas, 75246, United States

  • Exelixis Clinical Site #9

    RECRUITING

    Myrtle Beach, South Carolina, 29572, United States

  • Exelixis Clinical Site #90

    RECRUITING

    Florence, 50134, Italy

  • Exelixis Clinical Site #91

    WITHDRAWN

    Paris, 75015, France

  • Exelixis Clinical Site #92

    RECRUITING

    Marseille, 13273, France

  • Exelixis Clinical Site #93

    RECRUITING

    Jena, 07747, Germany

  • Exelixis Clinical Site #94

    RECRUITING

    Graz, 8036, Austria

  • Exelixis Clinical Site #95

    RECRUITING

    Tübingen, 72076, Germany

  • Exelixis Clinical Site #96

    RECRUITING

    Bordeaux, 33000, France

  • Exelixis Clinical Site #97

    RECRUITING

    Middlesex, HA6 2RN, United Kingdom

  • Exelixis Clinical Site #98

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Exelixis Clinical Site #99

    RECRUITING

    London, W6 8RF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.